Contents

Search

insulin aspart (NovoLog, Fiasp, Merilog)

Synthetic proinsulin with more rapid onset & shorter duration of action than regular insulin, similar to insulin lispro. Dosage: -> may mix with NPH, but not other insulins Pharmacokinetics: -> absorbed faster after SQ injection than insulin, but slightly slower than Humalog Mechanism of action: -> 1 lysine & 1 proline residue of insulin substituted with aspartate residue [2] Notes: Novo Nordisk manufacturer.

Interactions

drug adverse effects of hypoglycemic agents

Related

lisproinsulin (Humalog, Lispro, Admelog, HumaPenn Memoir, HumaPenn Luxura HD, Humalog U-200 KwikPen)

General

short-acting insulin

References

  1. Prescriber's Letter 8(2):supplement 2001
  2. Prescriber's Letter 8(10):58 2001
  3. Monaco K FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes. Approval makes Merilog the third insulin biosimilar. MedPage Today February 14, 2025 https://www.medpagetoday.com/endocrinology/type1diabetes/114245

Component-of

insulin aspart/neutral protamine aspart (aspart 70/30) insulin degludec/insulin aspart